ストックスクリーナーアプリを入手
11.71
14.96%
-2.06
アフターアワーズ：
11.69
-0.02
-0.17%
前日終値:
$13.77
開ける：
$12.98
24時間の取引高:
785.49K
Relative Volume:
1.68
時価総額：
$356.76M
収益：
-
当期純損益:
$-168.05M
株価収益率:
-2.2827
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
-22.09%
1か月 パフォーマンス:
-32.08%
6か月 パフォーマンス:
-24.89%
1年 パフォーマンス:
+0.34%
1日の値動き範囲:
$11.57
$13.09
1週間の範囲:
$11.57
$15.11
52週間の値動き範囲:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.71 | 419.52M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Biotech behind new DMD and ALS trials turns 2024 loss into 2025 profit - Stock Titan
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - Yahoo Finance
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks
Keros Therapeutics adds former Lyell CFO to board - Investing.com
Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan
Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan
Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan
Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan
Ex-Lyell CFO and healthcare banker Charles Newton joins Keros board - Stock Titan
KROS Technical Analysis & ETF Price Forecast - Intellectia AI
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics CEO to Present at Multiple Conferences - The Globe and Mail
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan
Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Tang Capital reports 0% stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Will Keros Therapeutics Inc. stock keep outperforming rivalsQuarterly Market Review & Community Verified Trade Alerts - mfd.ru
Can Keros Therapeutics Inc. reach all time highs this yearJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - mfd.ru
Keros Therapeutics, Inc. (KROS) Stock Analysis: Spotlight on a 37.72% Potential Upside in Biotech - DirectorsTalk Interviews
Is Keros Therapeutics Inc. likely to announce a buybackMarket Performance Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Why Keros Therapeutics Inc. stock could see breakout soon2025 Market Sentiment & Smart Allocation Stock Tips - mfd.ru
What analyst consensus says on Keros Therapeutics Inc. stockQuarterly Growth Report & Safe Entry Momentum Tips - mfd.ru
How much upside does Keros Therapeutics Inc. haveWeekly Trading Summary & Real-Time Buy Signal Alerts - mfd.ru
Keros Therapeutics: Key Catalysts and Financial Runway in Focus - AD HOC NEWS
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
How Keros Therapeutics Inc. stock benefits from global expansion2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc. - MarketBeat
Big Picture: What is SIDUs revenue forecastGap Up & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):